Sanofi Bets Big On IgM ‘Super Antibodies’ In Potential $6bn Cancer and Immunology Deal
IGM Biosciences Is Leader In Novel Field
Looking to catch up with leaders in in the field of next-generation antibodies, Sanofi has struck a deal with IGM Biosciences for three cancer and three auto-immune/inflammation IgM candidates that hold the promise of greater efficacy.
You may also be interested in...
It is time for In Vivo's 15th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.
The French major saw strong Q3 sales and raised its business guidance accordingly, but the discontinuation of an early-stage trial has added to a growing list of setbacks the firm has faced in reviving its oncology pipeline.